PharmaResources (Shanghai) Co. Ltd. A (SHE:301230) — Market Cap & Net Worth
Market Cap & Net Worth: PharmaResources (Shanghai) Co. Ltd. A (301230)
PharmaResources (Shanghai) Co. Ltd. A (SHE:301230) has a market capitalization of $684.88 Million (CN¥4.68 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #10867 globally and #3044 in its home market, demonstrating a 2.44% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaResources (Shanghai) Co. Ltd. A's stock price CN¥33.53 by its total outstanding shares 139586605 (139.59 Million). Review debt load of PharmaResources (Shanghai) Co. Ltd. A to assess the company's total debt and financial obligations.
PharmaResources (Shanghai) Co. Ltd. A Market Cap History: 2022 to 2026
PharmaResources (Shanghai) Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $582.11 Million to $684.88 Million (5.80% CAGR).
PharmaResources (Shanghai) Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaResources (Shanghai) Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.89x
PharmaResources (Shanghai) Co. Ltd. A's market cap is 0.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.79x
PharmaResources (Shanghai) Co. Ltd. A's market cap is 17.79 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $582.11 Million | $478.88 Million | $67.18 Million | 1.22x | 8.67x |
| 2023 | $552.61 Million | $489.72 Million | $37.62 Million | 1.13x | 14.69x |
| 2024 | $521.27 Million | $544.47 Million | $17.08 Million | 0.96x | 30.51x |
| 2025 | $610.12 Million | $688.35 Million | $34.29 Million | 0.89x | 17.79x |
Competitor Companies of 301230 by Market Capitalization
Companies near PharmaResources (Shanghai) Co. Ltd. A in the global market cap rankings as of June 19, 2026.
Key companies related to PharmaResources (Shanghai) Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
PharmaResources (Shanghai) Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, PharmaResources (Shanghai) Co. Ltd. A's market cap moved from $582.11 Million to $ 684.88 Million, with a yearly change of 5.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥684.88 Million | +12.25% |
| 2025 | CN¥610.12 Million | +17.05% |
| 2024 | CN¥521.27 Million | -5.67% |
| 2023 | CN¥552.61 Million | -5.07% |
| 2022 | CN¥582.11 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of PharmaResources (Shanghai) Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $684.88 Million USD |
| MoneyControl | $684.88 Million USD |
| MarketWatch | $684.88 Million USD |
| marketcap.company | $684.88 Million USD |
| Reuters | $684.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates. It serves global pharmaceutical and biotechnology companies.… Read more